Eli Lilly's Executive Signals Increased M&A Activity as Company Expands
Eli Lilly, led by Jacob Van Naarden, has significantly increased its acquisition spending this year compared to the previous one. The company is leveraging strong financial performance from GLP-1 drugs like Mounjaro and Zepbound to fund new deals across various therapeutic areas.
Tickers: $LLY